NCT01830244View on ClinicalTrials.gov

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

June 30, 2020

Conditions
Breast Cancer
Interventions
DRUG

Nab-Paclitaxel

Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks

Trial Locations (5)

2065

Royal North Shore Hospital, Sydney

2200

Bankstown Lidcome Hospital, Bankstown

3220

Barwon Health, Geelong

St John of God Healthcare, Geelong, Geelong

3280

South West Healthcare, Warrnambool

Sponsors

Lead Sponsor

Barwon Health
All Listed Sponsors
lead

Barwon Health

OTHER_GOV

NCT01830244 - IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer | Biotech Hunter | Biotech Hunter